---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-23-000053"
form_type: "8-K/A"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T16:51:27.405943+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Supernus Q2 2023 revenues $135.5M, down 20% YoY; GAAP operating loss $17.6M

## Summary
- Qelbree net sales $31.0M (+179%), GOCOVRI $28.8M (+17%) in Q2 2023 vs Q2 2022.
- Trokendi XR net sales fell 73% in Q2 and 60% in H1 2023 due to generic erosion.
- GAAP net loss ($0.8M) or ($0.02)/diluted share; adjusted operating earnings $10.0M vs $37.6M.
- Cash & securities $189.1M at June 30, 2023, down from $555.2M due to $402.5M note repayment.
- Full-year 2023 guidance reaffirmed: total revenue $580-$620M, GAAP operating loss $(30)-$(10)M.

## SEC filing metadata
- accession: 0001356576-23-000053
- form_type: 8-K/A
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000053/0001356576-23-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000053/supn-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-23-000053
- JSON: https://secwatch.observer/filing/0001356576-23-000053.json
- Plain text: https://secwatch.observer/filing/0001356576-23-000053.txt

## Key facts
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release announcing its results of operations and financial condition for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000053/0001356576-23-000053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.